Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Stasi, Cristina ^a,b   Triboli, Elisa ^a,b   Arena, Umberto ^a,b   Urraro, Teresa ^a,b   Petrarca, Antonio ^a,b   Gragnani, Laura ^a,b   Laffi, Giacomo ^a,b   Zignego, Anna L ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Elastography; Hepatitis C virus infection; Mixed cryoglobulinemia; Rituximab

Indexed keywords

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; CRYOGLOBULINEMIA; DEMOGRAPHY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED;

EID: 84892768137     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-21     Document Type: Article

References (53)

1. Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E, Romagnani S, Gentilini P, Bréchot C. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992, 15:382-386.
2. la Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995, 38:1859-1860. 10.1002/art.1780381222, 8849361.
3. Louer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52. 10.1056/NEJM200107053450107, 11439948.
4. Craxì A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008, 29:85-95. 10.1016/j.mam.2007.09.017, 18177700.
5. Ferri C, Greco F, Longombardo G. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991, 9:621-624.
6. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia [see comments]. N Engl J Med 1992, 327:1490-1495. 10.1056/NEJM199211193272104, 1383822.
7. Zignego AL, Bréchot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999, 31:369-376. 10.1016/S0168-8278(99)80239-6, 10453955.
8. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007, 39:2-17. 10.1016/j.dld.2006.06.008, 16884964.
9. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004, 33:355-374. 10.1016/j.semarthrit.2003.10.001, 15190522.
10. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, de Vita S, Ferri C, Mazzaro C, Migliaresi S, Ossi E, Pietrogrande M, Gabrielli A, Galli M, Invernizzi F. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005, 165:101-105. 10.1001/archinte.165.1.101, 15642884.
11. Ferri C, la Civita L, Cirafisi C, Siciliano G, Longombardo G, Bombardieri S, Rossi B. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992, 19:889-895.
12. Pietrogrande M, de Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454. 10.1016/j.autrev.2011.01.008, 21303705.
13. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, de Vita S. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55. 10.1016/j.autrev.2011.07.005, 21821153.
14. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
15. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, Matucci-Cerinic M, Bosi A, Laffi G, Zignego AL. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010, 116:335-342. 10.1182/blood-2009-11-253948, 20308604.
16. Arena U, Vizzuti F, Abraldes J, Corti G, Stasi C, Moscarella S, Milani S, Lorefice E, Petrarca A, Romanelli RG, Laffi G, Bosch J, Marra F, Pinzani M. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008, 57:1288-1293. 10.1136/gut.2008.149708, 18448567.
17. Stasi C, Arena U, Vizzutti F, Zignego AL, Monti M, Laffi G, Corti G, Pinzani M. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool?. Dig Liver Dis 2009, 41:863-866. 10.1016/j.dld.2009.04.002, 19482565.
18. Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, Pinzani M. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis 2013, 45:840-843. 10.1016/j.dld.2013.03.023, 23660078.
19. Coco B, Olivieri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007, 14:360-369. 10.1111/j.1365-2893.2006.00811.x, 17439526.
20. Sagir A, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008, 47:592-595.
21. de Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853. 10.1002/art.34331, 22147661.
22. Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G, Gentilini P. T (14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000, 31:474-479. 10.1002/hep.510310230, 10655273.
23. Zignego AL, Ferri C, Giannini C, Monti M, la Civita L, Careccia G, Longombardo G, Lombardini F, Bombardieri S, Gentilini P. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996, 124:31-34. 10.7326/0003-4819-124-1_Part_1-199601010-00006, 7503475.
24. Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, Giannini C, Boni P, Sabattini E, Pileri S, Tura S, Bernardi M. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998, 129:294-298. 10.7326/0003-4819-129-4-199808150-00005, 9729182.
25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293. 10.1002/hep.510240201, 8690394.
26. Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D'Errico A, Zironi G, Grigioni W, Bolondi L. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997, 27:979-985. 10.1016/S0168-8278(97)80140-7, 9453422.
27. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649. 10.1002/bjs.1800600817, 4541913.
28. Guido M, Rugge M. Liver fibrosis: natural history may be affected by the biopsy sample. Gut 2004, 53:1878.
29. Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013, 20:e107-e114. 10.1111/jvh.12017, 23490377.
30. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54. 10.1002/hep.20506, 15690481.
31. Castera L, Vergniol J, Foucher J, le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, de Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350. 10.1053/j.gastro.2004.11.018, 15685546.
32. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713. 10.1016/j.ultrasmedbio.2003.07.001, 14698338.
33. Foucher J, Chanteloup E, Vergniol J, Castéra L, le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006, 55:403-408. 10.1136/gut.2005.069153, 1856085, 16020491.
34. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56:968-973. 10.1136/gut.2006.111302, 1994385, 17255218.
35. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48:442-448.
36. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006, 239:425-437. 10.1148/radiol.2392050505, 16641352.
37. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009, 83:127-134. 10.1016/j.antiviral.2009.04.002, 19443053.
38. Arima Y, Kawabe N, Hashimoto S, R Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Kobayashi K, Ichino N, Osakabe K, Nishikawa T, Okumura A, Ishikawa T, Yoshioka K. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res 2010, 40:383-392. 10.1111/j.1872-034X.2009.00618.x, 20236358.
39. Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-Cisneros J, Pineda JA. Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother 2010, 65:2204-2211. 10.1093/jac/dkq272, 20656678, Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.
40. Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol 2010, 25:964-969.
41. Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One 2012, 7:e47715. 10.1371/journal.pone.0047715, 3474716, 23082200.
42. Yuseff MI, Pierobon P, Reversat A, Lennon-Duménil AM. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol 2013, 13:475-486. 10.1038/nri3469, 23797063.
43. Leandro MJ, de la Torre I. Translational minireview series on B cell-directed therapies: the pathogenic role of B cells in autoantibody-associatedautoimmune diseases-lessons from B cell depletion therapy. Clin Exp Immunol 2009, 157:191-197. 10.1111/j.1365-2249.2009.03978.x, 2730844, 19604258.
44. Zha B, Wang L, Liu X, Liu J, Chen Z, Xu J, Sheng L, Li Y, Chu Y. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease. PLoS One 2012, 7:e49835. 10.1371/journal.pone.0049835, 3506658, 23189166.
45. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541. 10.1182/blood-2010-07-294249, 3031478, 20962324.
46. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. Am J Gastroenterol 2008, 103:2488-2494. 10.1111/j.1572-0241.2008.02040.x, 18775023.
47. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003, 74(3):360-369. 10.1189/jlb.0303093, 12949239.
48. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583. 10.1002/art.24249, 2637937, 19180481.
49. Smith V, van Praet JT, Vandooren B, van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, de Keyser F. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197. 10.1136/ard.2008.095463, 19103636.
50. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966. 10.2353/ajpath.2006.060205, 1698806, 16936269.
51. Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 2012, 14:R145. 10.1186/ar3879, 3446529, 22697462.
52. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462. 150999, 12045259.
53. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B. German Chronic Lymphocytic Leukemia Study Group Rituximab therapy of patients with B-cell chronic lymphocytic leukaemia. Blood 2001, 98(5):1326-1331. 10.1182/blood.V98.5.1326, 11520778, German Chronic Lymphocytic Leukemia Study Group.